Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Asha Das, MD
Tocagen Inc.
Study Director - Steven Kalkanis, MD
Henry Ford Hospital
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Uc Irivine
Irvine, California, United States
- Ucla
Los Angeles, California, United States
- Uc San Diego, Moores Cancer Center
San Diego, California, United States
- Henry Ford Hospital
Detroit, Michigan, United States
- Jfk Medical Center New Jersery
Edison, New Jersey, United States
- Cleveland Clinic Foundation
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2014
- Primary completion
- 3 Mar 2016
- Completion
- 3 Mar 2016
- Last update posted
- 21 May 2018
- Registered enrollment
- 17
- Registry id
- NCT01985256
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.